Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial

被引：0
|
作者：
Pressiani, T. [1 ]
Balsano, R. [2 ]
Giordano, L. [3 ]
Milella, M. [4 ,5 ]
Bergamo, F. [6 ]
Bozzarelli, S. [7 ]
Noventa, S. [8 ]
Ferrari, D. [9 ]
Scartozzi, M. [10 ,11 ]
Parra, H. J. Soto [12 ]
Auriemma, A. [4 ,5 ]
Solda, C. [13 ]
Zaniboni, A. [8 ]
Zecchetto, C. [4 ,5 ]
Rizzato, M. D. [6 ]
Rimassa, L. [14 ]
Santoro, A. [15 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Rozzano, Italy
[2] Humanitas Univ, IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Dept Biomed Sci,Humanitas Canc Ctr, Rozzano, Italy
[3] IRCSS Humanitas Res Hosp, Biostat Unit, Humanitas Canc Ctr, Rozzano, Italy
[4] Univ Verona, Sect Innovat Biomed, Dept Engn Innovat Med DIMI, Oncol Area, Verona, Italy
[5] Verona Univ & Hosp Trust, Verona, Italy
[6] IRCCS, Veneto Inst Oncol IOV, Dept Oncol, Oncol 1, Padua, Italy
[7] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Rozzano, Italy
[8] Fdn Poliambulanza Ist Osped, Med Oncol Unit, Brescia, Italy
[9] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol Dept, Med Oncol & Hematol Unit,AO S Paolo, Milan, Italy
[10] Univ Monserrato, Med Oncol, Monserrato, Italy
[11] Univ Hosp, Monserrato, Italy
[12] Azienda Osped Univ Policlin San Marco, Oncol Med, Catania, Italy
[13] IRCCS, Veneto Inst Oncol IOV, Oncol 1, Dept Oncol, Padua, Italy
[14] Humanitas Univ, Med Oncol & Hematol Unit, Dept Biomed Sci, Humanitas Canc Ctr,IRCCS Humanitas Res Hosp, Rozzano, Italy
[15] Humanitas Univ, Med Oncol & Hematol Unit, Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Rozzano, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.291
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285P
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [21] Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP)
    Li, Rentao
    Liu, Yang
    Liu, Yayue
    Fu, Linlin
    Qi, Qi
    Zhang, Xihao
    Cui, Yunlong
    Lu, Wei
    Li, Huikai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
    Huh, Gunn
    Lee, Hee Seung
    Choi, Jin Ho
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [23] Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
    Nagata, Y.
    Kinoshita, C.
    Ishimoto, U.
    Kano, T.
    Ishikawa, M.
    Mikuni, H.
    Nakatsuka, K.
    Harada, K.
    Nishimura, T.
    Noguchi, M.
    Sawada, R.
    Amano, K.
    Saruta, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wan-Rui
    Li, Xiaofen
    Tian, Bole
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
    Zhu, Huayun
    Sun, Xiaofeng
    Pan, Xuan
    Wu, Pingping
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer: Closing the GAP
    Roth, Marc T.
    Goff, Laura W.
    JAMA ONCOLOGY, 2019, 5 (06) : 831 - 832
  • [27] Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial
    Jin, Shui-Ling
    Qiao, Shishi
    Li, Ren-Feng
    Zhang, Weijie
    He, Wei
    Su, Chang
    Li, Lu-Hao
    Pan, Jie
    Guo, Wen-Zhi
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 498 - 498
  • [28] Phase II study of gemcitabine and oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer
    Kim, H.
    Lee, S.
    Bae, S.
    Kim, C.
    Lee, N.
    Lee, K.
    Park, S.
    Won, J.
    Hong, D.
    Park, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepitheliomalikecarcinoma: A Multicenter, Single-Arm, Phase II Trial
    Zhou, C.
    Lin, X.
    Li, S.
    Sun, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S96 - S97
  • [30] Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Borad, Mitesh J.
    Laheru, Daniel A.
    Smith, Lon S.
    Wood, Tina E.
    Korn, Ronald L.
    Desai, Neil
    Trieu, Vuong
    Iglesias, Jose L.
    Zhang, Hui
    Soon-Shiong, Patrick
    Shi, Tao
    Rajeshkumar, N. V.
    Maitra, Anirban
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4548 - 4554
12345